Akeso Publishes Preclinical Results of TIGIT monoclonal antibody(AK127)at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

HONG KONG, April 14, 2022 /PRNewswire/ — Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT monoclonal antibody (AK127) showing potent preclinical anti-tumor activities at the American Association for Cancer Research (AACR) Annual Meeting 2022.

AbstractAK127, a novel monoclonal antibody (mAb) targeting T cell immunoreceptor (TIGIT)


AK127 is a novel humanized immunoglobulin (Ig) G1 monoclonal antibody (mAb) targeting T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT). AK127 specifically binds to TIGIT and blocks the interaction of TIGIT with its ligands, thus relieving immune suppression and promoting anti-tumor immune response.

Immune checkpoint blocking antibodies achieved great clinical success, yet a large fraction of cancer patients receive minimum benefit from current immunotherapies targeting PD-1 and CTLA-4. As a new multifunctional immune checkpoint molecule, TIGIT holds promise to become an important cancer immune therapy target.

The observations in AK127’s preclinical study support the development of AK127 as an anti-tumor agent in the clinic

  • AK127 blocked the immune inhibitory signal mediated by TIGIT, resulting in enhanced IL-2 secretion.
  • AK127 exhibited binding to FcγRIa, FcγRIIIa and C1q, and eliciting ADCC, ADCP and CDC.
  • In animal models, both AK104 (0.5 mg/kg) and AK127 (4 mg/kg) significantly inhibited tumor growth.
  • The combination of AK127 and AK104 produced a significantly enhanced anti-tumor effect than either monotherapy, demonstrating the synergistic anti-tumor activity of AK127 combined with AK104.